Empli03, an oral buccal tablet with extended release for the treatment of chronic pain, aims to reduce the risk for opioid abuse and addiction through the Emplior platform.

Chronic pain is a growing health issue globally and, in the US, as many as 20% of the population is estimated to suffer from chronic pain and in need of longterm pain relief. Widespread chronic pain is a problem that is associated with high costs for society and individual patients. Opioids are, and will continue to be, an important class of treatments for moderate to severe chronic pain.

Empli03 is being developed as an oral buccal tablet for chronic pain, which can reduce the risk for abuse by achieving stable pain relief, improved controlled release and resist mechanical impact to manipulate. It is patient-friendly, the patient simply places Empli03 under the upper lip for up to several hours, and can conclude the treatment by just removing the tablet.



The Amp01 project targets the tobacco-free dry oral nicotine pouches market

Dry, white, tobacco-free oral nicotine pouches contribute to the fast-growing market of nicotine pouches due to a sharp increase in health awareness that creates interest in nicotine products that are neither heated nor inhaled.


Do you want to know more?

Contact us today.